Finerenone for primary membranous nephropathy
Treatments studied
Part of Kidney & urinary clinical trials.
This trial tests if finerenone, a medicine that may protect the kidneys, can help people with primary membranous nephropathy (a kidney disease that causes protein in urine). It is for adults who are already taking a standard blood pressure medicine but still have protein in their urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have primary membranous nephropathy.
- You have been taking a maximum tolerated dose of an ACE inhibitor or ARB (blood pressure medicine) for at least 4 weeks.
- Your blood pressure is 140/90 mmHg or lower.
- Your urine protein level is between 1.0 and 5.0 grams per day.
- Your kidney function (eGFR) is 60 or higher.
- You have not used steroids, immunosuppressants, or other study drugs in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
This trial tests if finerenone can protect kidneys in people with chronic kidney disease who are not taking common blood pressure medications called ACE inhibitors, ARBs, or renin inhibitors. It may help slow kidney damage.
This study tests a once-daily pill called finerenone to see if it can reduce protein in the urine (a sign of kidney damage) in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and slow down disease progression.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.